cyrilzakka/clinical-trials huggingface dataset:
Genetics of the Combined Pulmonary Fibrosis and Emphysema Syndrome

The combined pulmonary fibrosis and emphysema syndrome (CPFE) individualized by our group in 2005 is characterized by an often severe dyspnea, almost exclusive male predominance, and often major, profound impairment of gas exchange contrasting with preserved lung volumes and absence of airflow obstruction, and a high risk of pre-capillary pulmonary hypertension responsible for increased mortality. Almost all patients are smokers or ex-smokers. There are some arguments in favor of genetic abnormalities in this syndrome of unknown etiology (other than smoking) including short telomeres and mutations in the telomerase complex genes. There are also emphysematous lesions, in patients with familial pulmonary fibrosis, with mutations in the SFTPC gene (surfactant protein C), and reported cases of CPFE syndrome with SFTPC mutation. No large genetic studies have been conducted to date in the CPFE syndrome. Our main hypothesis is that the proportion of subjects with short telomeres is higher among patients with CPFE syndrome than in subjects of similar age with idiopathic pulmonary fibrosis but without emphysema. It has previously been shown that mutations in the telomerase TERT or TERC genes are mostly found in people whose telomeres are abnormally short. The investigators propose to use that test to identify patients most likely carrying a mutation, and to seek, among them, the mutations in the TERT or TERC telomerase genes. The objective of the study is to compare the proportion of patients with short telomeres in the group of patients with CPFE syndrome to that of other patients (with idiopathic pulmonary fibrosis without emphysema, or with emphysema without fibrosis).


Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 80 years old.
* Patient with Idiopathic Pulmonary Fibrosis Or
* Patient with emphysema Or
* Patient with combined pulmonary fibrosis and emphysema syndrome Or
* Patient reporting no chronic lung disease

Exclusion Criteria:

* Other causes of interstitial lung disease or context:

  * Connective
  * Pneumonia drug
  * Pneumoconiosis
  * Sarcoidosis
  * histiocytosis, lymphangioleiomyomatosis, etc.
* Refusal to participate in the study or to sign the consent
* Inability to give informed about the information
* Woman breastfeeding or pregnant
* No coverage for Social Security
* Deprivation of Civil Rights
The Genetic Basis for Atrial Fibrillation

Atrial fibrillation (AF) is reaching epidemic proportions in the aging U.S. and European populations, but the mechanisms of increased susceptibility to atrial fibrillation are still unknown. In this study, we look to further examine genetic and medical co-morbidity influence of atrial fibrillation duration and response to medications. In Specific Aim 1, we propose the creation of a Veterans Affairs AF Biorepository (VAAFBio), which is a resource that will collect and store clinical, demographic, blood and DNA samples from patients with atrial fibrillation to aide this study and future studies of this type in the VA population. In Specific Aim 2, examine common genetic polymorphisms in veteran patients with atrial fibrillation and examine gene-environment interactions with risk factors for atrial fibrillation.

Atrial fibrillation (AF) is reaching epidemic proportions in the aging U.S. and European populations, but the mechanisms of increased susceptibility to atrial fibrillation are still unknown. In this study, the investigators look to further examine genetic and medical co-morbidity influence of atrial fibrillation duration and response to medications. In Specific Aim 1, the investigators propose the creation of a Veterans Affairs AF Biorepository (VAAFBio), which is a resource that will collect and store clinical, demographic, blood and DNA samples from patients with atrial fibrillation to aide this study and future studies of this type in the VA population. In Specific Aim 2, the investigators will examine common genetic polymorphisms in veteran patients with atrial fibrillation and examine gene-environment interactions with risk factors for atrial fibrillation.

Patients will be identified through the VA inpatient and outpatient clinic, and will be approached for inclusion in the study. The target enrollment for the research and biorepository is 600 participants. A detailed family history, medical background, study questionnaires and a blood sample will then be obtained by the principal investigator or a research coordinator, following written informed consent under a protocol approved by the Jesse Brown VA Institutional Review Board. Once enough samples are collected, coded DNA samples will be sent out to analyze for linkage to known/candidate loci for AF.

Eligibility Criteria:
Inclusion Criteria:

* Subjects must be at least 18 years of age, and up to 100.
* Subjects must have a documented history of atrial fibrillation by ECG, ECHO, and or Holter monitor event recorder.
* Subjects must be willing to give written, informed consent.

Exclusion Criteria:

* Patients with a history of AF or atrial flutter that is only associated with cardiac surgery will be excluded from the study.
* Subjects who cannot speak English will be excluded from the study.
Gastric Per-Oral Endoscopic Myotomy (G-POEM) for the Treatment of Gastroparesis

Gastric Per-Oral Endoscopic Myotomy (G-POEM) is a procedure for the Treatment of Gastroparesis.

Gastroparesis is a disease of the stomach where there is significant delay in gastric emptying of contents to the intestines. This disease results in a multitude of symptoms including nausea, vomiting, weight loss, and malnutrition.

Current treatments for gastroparesis include dietary changes, oral medications (prokinetic agents to enhance gastric motility, acid reducers, anti-emetics to reduce nausea and vomiting), gastric stimulators and rarely surgery.

G-POEM (Gastric Per-Oral Endoscopic Myotomy-creating a cut in the muscle that controls gastric emptying), an incision-less (no cutting of the surface of the body) endoscopic procedure, is increasingly being performed to assist in the management of certain groups of patients with gastroparesis.

This data will be used for research purposes only to determine the clinical impact of endoscopic treatments on gastroparesis. The physicians will also be able to better understand the patient's condition and disease process that may lead to improved standard of care and improved patient management.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age
* Referral for endoscopic treatment of Gastroparesis for symptom management

Exclusion Criteria:

* \< 18 years of age
* Absence of gastroparesis based on scintigraphy studies
Endodontic Medications for Irreversible Pulpitis: Articaine or Eugenol?

The objective of the study is to determine which of the two commonly used endodontic medications (Eugenol VS Articaine) is most effective in controlling postoperative pain in irreversible pulpitis of the mature permanent tooth in adults. To do so, an assessment of the pain felt by patients will be carried out a few days apart. The supposed results are that the medications are equivalent in terms of effectiveness on the pain, but could then present different economic arguments

In irreversible pulpitis of the mature permanent tooth, the enrolled patients receive endodontic medications (Eugenol or Articaine) in order to determine which one is the more efficient to control the pain.

These patients would have received the same medication without this study. That's why this is an obsevationnal study.

Eligibility Criteria:
Inclusion Criteria:

* Adult patient, major, affiliated to a social health insurance scheme
* Patient having agreed to participate in the study
* Urgent consultant patient for irreversible pulpitis
* Patient understanding French

Exclusion Criteria:

* Refusal of the patient to participate in the study
* Impossibility of performing the surgical procedure
* Impossibility to give the subject information enlightened (difficulty of understanding ...)
* Subject under the protection of justice, or under guardianship
* General contraindication to endodontic treatment in 2 sessions (high risk of infectious endocarditis, for example)
* Chronic intake of analgesic drugs
Comparison of Twice Weekly Versus Daily Iron Therapy in Treating Anemia in Children With Cerebral Palsy

a randomized clinical trial to compare the effect of twice weekly versus daily iron therapy in treating anemia in children with cerebral palsy, to be conducted at Department of pediatric medicine children's hospital PIMS islamabad.

a total of 160 children of either gender with age between 6 and 60 months diagnosed with cerebral palsy and concomitant iron deficiency anemia will be enrolled, they will be allocated two groups by lottery method. one group will be given ferrous sulphate 3mg/kg daily in the form of syrup and other group will be given ferrous sulphate 3mg/kg twice weekly in the form of syrup for a period of 4 weeks. the primary outcome will be measured as rise in hemoglobin levels more than or equal to 1g/dl at 4 weeks.

Eligibility Criteria:
Inclusion Criteria:

1. All the children with cerebral palsy who are diagnosed cases of iron deficiency anaemia
2. Age 06 months to 5 years
3. Both genders

Exclusion Criteria:

1. \>5 years of age
2. Children with severe anaemia requiring transfusion (Hb\<5 g/L)
3. Children with history of taking oral/IV iron supplements or repeated blood transfusions during last one month
4. Children with concomitant diarrheal disease
5. Where parents are not willing to participate in the study
Molecular and Cellular Characterization of Skull Base Tumors

The purpose of the study is to analyze biological samples and genetic material for basic science research investigating the molecular and cellular characterization of skull base tumors.

The overall goal of this proposal is to determine new molecular and cellular features that define tumor subtypes that are clinically actionable, may drive important changes in patient management, and/or elucidate novel chemotherapeutic options. Skull base tumors are currently diagnosed based on histopathologic criteria, on which post-operative management is based. However, the investigators hypothesize that each tumor type (eg. chordoma or chondrosarcoma) will have molecular and/or cellular subcategories that will redefine how to categorize and diagnose patients, predict clinical outcome, and optimally design a patient-specific management strategy. In addition, we aim to catalogue changes that occur after treatment after surgical resection, chemotherapy, and/or radiation by comparing primary and recurrent tumors.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of a skull base tumor

Exclusion Criteria:

* Insufficient tumor sample at time of resection
Validation of DNA Methylation Biomarkers for Oral Cancer Detection

The aim of this study is to evaluate the association between several methylated genes and oral cancers. A prospective case control trial is designed with sample size estimated at least 160 cases. It is expected to enroll at least 100 subjects with precancerous lesion or oral cancer, and \~60 subjects with normal oral mucosa. This study is approved by the National Taiwan University Hospital Research Ethics Committee. After signing the informed consent, all of the subjects will receive an intraoral examination and the oral epithelial cells will be collected. If abnormal oral lesion is observed, it will be photographed, and the biopsy will be performed to confirm the diagnosis. For methylated gene detections, the gDNA will be extracted from the collected cells and standardized assay will be performed. Clinical sensitivity and specificity for these methylated genes will be evaluated.


Eligibility Criteria:
Inclusion Criteria:

* Subject with age over 20.
* Subject agrees to sign the informed consent form.

Exclusion Criteria:

* Subjects have history of head and neck cancer.
* Subjects have had received chemotherapy for cancers.
* Pregnant Woman
* Subjects whose has oral mucosal lichen planus.
* Subjects whose oral mucosal findings is abnormal, but the diagnosis is unknown.
Use of Discarded Surgery Human Tissue Specimens for Basic Science Research

Although it is now established that calcification process result from the joint and coordinated action of different cell types, many areas of shadow remain regarding the spatio-temporal implementation of these events. Highlighting these processes requires additional research to consider new approaches to clinical management of patients with such conditions. It is in this context that the investigators need to use residual human tissue fragments resulting from surgery which are not intended to be used for clinical-biological management of patients. The use of these pseudonymised human tissues will allow the investigators to conduct in vitro cell culture experiences.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing surgery in the Cardiac Surgery and Orthopedic Surgery departments of the CHU Amiens-Picardie
* patients who will be beforehand informed
* patients who will not be opposed to this study.

Exclusion Criteria:

* HIV and hepatitis positive patients
Tramadol Versus Placebo in the Management of Postoperative Pain Following Bunionectomy

The study evaluates the effectiveness and safety of IV tramadol compared to placebo managing postoperative pain following a bunionectomy

(Non-clinical summary)

Tramadol is a centrally-acting synthetic analgesic of the aminocyclohexanol group with opioidlike effects. Tramadol is extensively metabolized following administration, which results in a number of enantiomeric metabolites that display different opioid-receptor binding properties, and monoaminergic reuptake inhibition.

Eligibility Criteria:
Key Inclusion Criteria:

* The patient is male or female 18-75 years of age undergoing unilateral first metatarsal bunionectomy surgery
* Willing to give consent and able to understand the study procedures
* Female patients must be of non-childbearing potential or be practicing a highly effective contraception
* The patient must be willing to be housed in a healthcare facility and able to receive parenteral analgesia for at least 72 hours after surgery.
* The patient meets definition of American Society of Anesthesiologists (ASA) Physical Class 1, or 2.

Exclusion Criteria:

* Patient is not expected to receive a continuous infusion nerve block as described in the Post-Op anesthetic procedures protocol
* Patient is undergoing bilateral or revision bunionectomy surgery
* The patient has allergy or hypersensitivity (or is intolerant) to opioids or tramadol The patient has known physical dependence on opioids
* The patient has taken other prior/concurrent chronic medications that have not been at a stable dose for at least 2 weeks prior to screening
* The patient is taking herbal or dietary supplements or medications that are moderate or strong inhibitors of CYP2D6 or CYP3A4 or inducers of CYP3A4
* The patient has taken monoamine oxidase (MAO) inhibitors, trazodone, or cyclobenzaprine within 14 days prior to surgery
* The patient cannot be withdrawn from medications (at least 7 days prior to surgery) that may lower the seizure threshold (e.g. anti-psychotic agents, MAOI inhibitors) or which increase serotonergic tone (e.g. selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, triptans).
* The patient has a history of epilepsy, or is known to be susceptible to seizures
* The patient has a history of Long QT Syndrome or a relative with this condition
* The patient has expressed suicidal ideation or is considered to be at risk of suicide.
* The patient is morbidly obese (body mass index \[BMI\] ≥ 40 kg/m2) or has documented sleep apnea requiring pharmacological or device intervention.
* Clinically significant abnormalities in the judgement of the Investigator
* The patient was administered an investigational product within 30 days prior to Screening.
* The patient has previously participated in a clinical study with AVE-901.
Image Guided Reirradiation of High-grade Glioma

The purpose of the study is to evaluate the short- and long term toxicity of radiotherapy to patients with recurrent high-grade glioma who have previously received radiotherapy and to determine the best dose and treatment regimen. Positron emission tomography (PET) using an amino acid tracer, 18-fluoro-ethyltyrosine (18F-FET), is used for target delineation.The study examines, in four sequential treatment groups, the effect of dose, hypofractionation and treatment volume on toxicity. Upon completion of the phase I part, the study progresses to phase II where the best dose- and treatment regimen will be chosen for treatment.


Eligibility Criteria:
Inclusion Criteria:

* recurrent high-grade glioma
* previous focal radiotherapy for high-grade glioma
* no standard treatment options available/indicated
* ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1 or 2
* life expectancy \> 3 months
* hemoglobin value \> 6 mmol/l (transfusion permitted)
* able to understand oral and written Danish

Exclusion Criteria:

* disseminated recurrent disease
* infection or wound dehiscence or other pathological condition in meninges/skull/scalp
* symptoms of elevated intracranial pressure
* very early recurrence following primary radiotherapy (\< or equal to 3 months)
* contraindications to magnetic resonance imaging (MRI) or positron emission tomography (PET)
* other previous radiotherapy to the brain than primary course of irradiation
High-Intensity vs Low-Intensity NPPV in Patients With an AECOPD: The HAPPEN Trial

To determine whether high-intensity NPPV, compared with low-intensity NPPV, could reduce the need for endotracheal intubation during hospitalization in patients with an AECOPD and hypercapnia.


Eligibility Criteria:
Inclusion Criteria:

* AECOPD confirmed by the 2019 criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
* Arterial pH \<7.35 and PaCO2 \>45 mmHg at screening entry
* PaCO2 \>45 mmHg after a 6-hour trial of low-intensity NPPV

Exclusion Criteria:

* Age \<18 years
* Excessive respiratory secretions with weak cough
* Upper airway obstruction
* Recent oral, facial, or cranial trauma or surgery
* Recent gastric or esophageal surgery
* Presence of restrictive ventilatory dysfunction (eg, consolidation or removal of at least one pulmonary lobe, massive pleural effusion, chest wall deformity, continuous strapping with thoracic or abdominal bandage, or severe abdominal distension)
* Active upper gastrointestinal bleeding
* Cardiac or respiratory arrest
* Arterial oxygen tension/fraction of inspired oxygen (PaO2/FiO2) \<100 mmHg
* Pneumothorax
* Obvious emphysematous bullae confirmed by chest CT scan
* Ventricular arrhythmia or myocardial ischemia
* Severe hemodynamic instability (mean arterial pressure \<65 mmHg)
* Severe metabolic acidosis (pH \<7.20 and bicarbonate \<22 mmol/L)
* Refusal to receive NPPV or give informed consent
* Prior endotracheal intubation or tracheostomy during the current hospitalization
* A do-not-intubate order
Diplegic Cerebral Palsy and Action Observation Training

In this study, video-based action observation training and live action observation training in children with spastic diplegic cerebral palsy; It was aimed to examine the effect on motor function, activity participation and secondary outcome measures.

The study was designed as a single-blind randomized controlled trial. Patients aged 5-14 years with spastic diplegic cerebral palsy will be included. Children will be assigned to groups through stratified randomisation; The patients will be divided into 3 groups as experimental and control groups. Group 1 (experiment): video-based action observation training in addition to the conventional rehabilitation program, Group 2 (experiment): live action observation training in addition to the conventional rehabilitation program, Group 3 (control) will receive only the conventional rehabilitation program. The experimental group will receive 20 minutes of action observation training after a conventional physiotherapy program for 20 minutes for 8 weeks, 40 minutes 2 days a week. The control group will receive 40 minutes of conventional treatment. Evaluations will be made for each group, before and 8 weeks after the start of the study. GMFM for gross motor function; Pediatric berg balance scale for balance function; Timed Up and Go Test for functional mobility assessment; Gillette Functional Assessment Questionnaire and 1-min walk test to assess functional walking; sit and stand test for functional muscle strength and to evaluate activity participation; The Child and Adolescent Participation Questionnaire (CASP) will be used.

Eligibility Criteria:
Inclusion Criteria:

* Being diagnosed with spastic diplegic cerebral palsy,
* To be between the ages of 5-14,
* To be at GMFCS I, II and III levels,
* To have the cognitive level to follow the instructions given by the researchers,
* IQ\> 70 (to be accessed from patient files),
* Those who do not have serious restrictions in joint movement,

Exclusion Criteria:

* Children with joint contractures,
* Not having visual impairment and visual field defect,
* Children who have had a seizure in the last 6 months or children who cannot be controlled despite seizure medication
* Those who received botulinum injections 6 months before the study.
Impact of Adjuvant Hormone Therapy on Bone and Cardiovascular Risk

Breast cancer is the most frequently observed cancer in women in France.The mortality rate is still decreasing with a decrease of 1.6% per year between 2010 and 2018, explained by the improvement in available treatments.For patients with breast cancer expressing hormone receptors, treatment with Tamoxifen or anti-aromatase can have the risk of the cancer coming back.However, these treatments have many side effects, including the risk of osteoporosis and metabolic disorders with anti-aromatases; and arterial and thromboembolic accidents with Tamoxifen.These effects have been well studied while taking hormone therapy.However, very few studies have analyzed the impact of these treatments after stopping them in women who have had non-metastatic hormone-sensitive breast cancer and uncertainties persist on the evolution of the health risk after initial treatment.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients who had T1-T3, N0-N2, M0 breast cancer
* Patients referred to the Menopause center in the context of their breast cancer who were included in the original study evaluating the bone impact of hormone therapy carried out between 2010 "Bone and cardiovascular impact of adjuvant hormone therapy for cancer non-metastatic breast "
* Patient who has given her consent for the study (written or verbal) after clear and fair information

Exclusion Criteria:

* Metastatic breast tumor
* Absence of adjuvant hormone therapy for patients whose tumor did not express hormone receptors
* Patients who have died since the last assessment
* Protected adult patient (guardianship, curatorship, safeguard of justice)